Aarti Drugs Limited

BSE: 524348 NSE: AARTIDRUGS
Aarti Drugs Limited - chemicals and materials in Thane, Maharashtra, India. FY 2026 financials & compliance.
CIN L37060MH1984PLC055433 Incorporated 28 September 1984 ROC Mumbai HQ Thane, Maharashtra, India
Active Listed - NSE: AARTIDRUGS · BSE: 524348 Public Limited Company chemicals and materials
Data last updated
Market Cap
₹4,063 Cr
AARTIDRUGS · NSE
Share Price
₹446.75
+0.36% today
Revenue
₹2,565 Cr
FY 2025-26 · +7.5% YoY
EBITDA
₹312 Cr
Margin 12.2%
Net Profit
₹195 Cr
FY 2025-26 · +15.9% YoY
P/E (TTM)
22.1x
P/B 2.8x
ROE
13.4%
ROCE 12.0%
Debt / Equity
0.41
Interest cover 14.8x

About Aarti Drugs Limited

Data last updated:

Aarti Drugs Limited is a public limited company based in Thane, Maharashtra, India. It operates in the specialty chemicals segment of the chemicals and materials sector. It was incorporated on 28 September 1984 and has been in existence for over 42 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L37060MH1984PLC055433. Its GSTIN is 27AAACA4410D1ZE (Maharashtra). The company holds 5 GST registrations, of which 4 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 524348 and NSE: AARTIDRUGS.

The company has an authorised share capital of ₹120 Cr and a paid-up capital of ₹91.27 Cr. It was formerly known as Aarti Drugs Private Limited. It is led by directors including Prakash Moreshwar Patil (Managing Director) and Harshit Manilal Savla (Managing Director).

Its last annual general meeting (AGM) was held on 24 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Plot No 198 MIDC Tarapurtal.Palghar Village Pamtermbhi, Thane, Maharashtra, India – 401506.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,565.31 Cr, a growth of 7.5% compared to the previous year. For the same year it recorded a net profit of ₹194.91 Cr (net margin 7.6%) and EBITDA of ₹311.78 Cr (EBITDA margin 12.2%). The net worth stands at ₹1,548.86 Cr (up 13.1% YoY). Total assets are valued at ₹2,130.64 Cr (up 7.1% YoY).

The company has about 1,012 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.

The company is associated with 2 brands: Aarti Drugs Ltd and Aarti Drugs. As per MCA filings, the company has open charges of ₹1,570 Cr and satisfied charges of ₹1,214.54 Cr on record. Court records list 133 cases involving the company, including 84 filed by the company and 49 filed against it; 35 cases are pending. The company has 45 deals on record (41 market trades, 4 buybacks); the latest was in May 2025. Its 7 peer companies in the Chemicals industry (API Manufacturers, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 3 smaller; the largest is Covalent Laboratories Private Limited with revenue of ₹2,693.24 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 80 overdue payments to 20 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aartidrugs.co.in.

Company details

CIN L37060MH1984PLC055433
Registration Number 055433
Incorporation Date 28 September 1984
ROC Mumbai
Listing Status Listed - Listed on NSE (AARTIDRUGS); Listed on BSE (524348)
Company Status Active
Date of Last AGM 24 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Aarti Drugs has one previous CIN (Corporate Identification Number): U37060MH1990PLC055433. The current CIN is L37060MH1984PLC055433, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L37060MH1984PLC055433Current
U37060MH1990PLC055433Previous
Key People
Prakash Moreshwar Patil Managing Director Harshit Manilal Savla Managing Director Rashesh Chandrakant Gogri Managing Director

Recognitions & Rankings of Aarti Drugs

India's Most Valuable Companies 2021 edition · Source: Hurun India
Rank#489
Valuation
₹5,804 Cr

Contact details

Aarti Drugs Limited's registered office is in Thane, Maharashtra. Its website is aartidrugs.co.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    aartidrugs.co.in
  • Registered Address
    Plot No 198 MIDC Tarapurtal.Palghar Village Pamtermbhi, Thane, Maharashtra, India – 401506
  • Industry
    Chemicals and Materials, Specialty Chemicals

To see the full contact details of Aarti Drugs Limited, buy the company report.

Comprehensive company report
Aarti Drugs Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Aarti Drugs operates two associated brands: Aarti Drugs Ltd and Aarti Drugs. Each brand links to its own profile.

BrandDescriptionWebsite
Aarti Drugs
APIs, intermediates, steroids, and formulations are manufactured.aartidrugs.co.in
Aarti Drugs Ltd
Manufacturing of Active Pharmaceutical Ingredients, Pharma Intermediates, and Specialty Chemicals in India.aartidrugs.com

Business activity

The main business activity of Aarti Drugs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Aarti Drugs Limited, buy the company report.

Financials of Aarti Drugs Limited

FY 2025-26 filings available

Aarti Drugs Limited reported revenue of ₹2,565.31 Cr (up 7.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,565 Cr
+7.5% YoY
EBITDA
₹312 Cr
+7.4% YoY
Profit After Tax
₹195 Cr
+15.9% YoY
Net Worth
₹1,549 Cr
+13.1% YoY
Total Assets
₹2,131 Cr
+7.1% YoY
Total Debt
₹577 Cr
-6.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,5652,3872,5292,7162,4892,1551,806
Revenue growth+7.5%-5.6%-6.9%+9.1%+15.5%+19.3%-
EBITDA312290321309333437266
EBITDA margin+12.2%+12.2%+12.7%+11.4%+13.4%+20.3%+14.7%
Profit before tax211212236224270369185
Net profit195168172166205280138
Net profit margin+7.6%+7.0%+6.8%+6.1%+8.2%+13.0%+7.6%
EPS (₹)21.3618.4218.6517.9622.1430.0960.69
Balance sheet
Total assets2,1311,9891,8491,8051,5981,2931,075
Net worth1,5491,3691,2821,1921,036913652
Total debt577615564609543351389
Cash & bank8.817.569.438.9622.339.787.64
Net working capital864831813946856661479
Cash flow
Cash from operations25424535913370.41155251
Cash from investing(173)(165)(224)(164)(150)(71.78)(33.21)
Cash from financing(77.44)(82.12)(136)16.5492.03(81.13)(215)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue826703720602653591677557
Revenue growth (YoY)+26.6%+19.0%+6.4%+8.1%+9.1%+6.3%--
Other income2.550.810.761.230.090.311.8711.90
EBITDA13596.1195.8055.0384.2874.0893.3361.73
EBITDA margin+16.4%+13.7%+13.3%+9.1%+12.9%+12.5%+13.8%+11.1%
Depreciation19.0018.4618.0417.9516.2614.7214.8813.80
Interest9.639.228.169.297.708.569.169.07
Profit before tax10969.2470.3629.0260.4151.1171.1650.76
Tax26.5119.1115.10(11.53)15.25(2.86)8.3913.67
Net profit82.7750.1355.2640.5545.1653.9762.7737.09
EPS (₹)9.075.496.054.444.955.916.884.06
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,2602,1742,2672,4982,2511,9151,635
Revenue growth+4.0%-4.1%-9.3%+11.0%+17.6%+17.1%-
EBITDA262265269286321401248
EBITDA margin+11.6%+12.2%+11.9%+11.5%+14.3%+21.0%+15.2%
Profit before tax181199192205256338175
Net profit169157142153195258129
Net profit margin+7.5%+7.2%+6.3%+6.1%+8.7%+13.5%+7.9%
EPS (₹)18.5417.2415.4316.5021.0627.6558.23
Balance sheet
Total assets1,8291,7711,6531,6531,5091,2251,034
Net worth1,4051,2511,1751,114972860622
Total debt421516475535519336378
Cash & bank4.704.573.822.682.213.813.85
Net working capital739752732875818623467
Cash flow
Cash from operations25422033716239.90154196
Cash from investing(128)(135)(187)(131)(125)(69.03)(29.35)
Cash from financing(126)(84.60)(149)(30.54)84.11(85.28)(168)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue706627632529579521623515
Revenue growth (YoY)+22.0%+20.4%+1.4%+2.8%+6.6%+5.7%--
Other income2.650.200.831.220.150.391.7111.37
Total expenses609538552486504457534454
EBITDA97.6089.8179.2842.3175.1963.9588.6560.25
EBITDA margin+13.8%+14.3%+12.6%+8.0%+13.0%+12.3%+14.2%+11.7%
Depreciation15.7115.2114.9514.8713.5512.2712.2112.02
Interest7.816.956.596.956.016.827.487.57
Profit before tax76.7367.8558.5721.7155.7845.2570.6752.03
Tax19.0517.0013.61(12.13)14.00(3.39)9.1913.50

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 06 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue826703720602653591677557
Revenue growth (YoY)+26.6%+19.0%+6.4%+8.1%+9.1%+6.3%--
Other income2.550.810.761.230.090.311.8711.90
EBITDA13596.1195.8055.0384.2874.0893.3361.73
EBITDA margin+16.4%+13.7%+13.3%+9.1%+12.9%+12.5%+13.8%+11.1%
Depreciation19.0018.4618.0417.9516.2614.7214.8813.80
Interest9.639.228.169.297.708.569.169.07
Profit before tax10969.2470.3629.0260.4151.1171.1650.76
Tax26.5119.1115.10(11.53)15.25(2.86)8.3913.67
Net profit82.7750.1355.2640.5545.1653.9762.7737.09
EPS (₹)9.075.496.054.444.955.916.884.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,5652,3872,5292,7162,4892,1551,806
Revenue growth+7.5%-5.6%-6.9%+9.1%+15.5%+19.3%-
Other income2.3916.364.032.1911.327.795.95
Total expenses2,2542,0972,2082,4072,1561,7171,541
Employee cost11699.6690.6080.4369.3065.8861.35
EBITDA312290321309333437266
EBITDA margin+12.2%+12.2%+12.7%+11.4%+13.4%+20.3%+14.7%
Depreciation66.9755.7851.4550.3250.0549.8848.75
Interest36.3039.0437.8937.1423.9126.2337.42
Profit before tax211212236224270369185
Tax15.9743.6763.9357.8364.9688.6143.89
Net profit195168172166205280138
Net profit margin+7.6%+7.0%+6.8%+6.1%+8.2%+13.0%+7.6%
EPS (₹)21.3618.4218.6517.9622.1430.0960.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital91.2791.2791.9492.6092.6093.2023.30
Reserves & surplus1,4581,2781,1901,100944820629
Shareholders' funds (net worth)1,5491,3691,2821,1921,036913652
Minority interest0.360.340.410.23(0.06)(0.02)0.00
Secured loans491496444507473235258
Unsecured loans85.5411912010270.25116131
Total debt577615564609543351389
Total liabilities2,1311,9891,8491,8051,5981,2931,075
Assets
Gross block1,7761,4941,3881,2051,1721,1011,035
Net block1,086866811676690665644
Capital work in progress21433026121076.7419.2612.21
Investments27.3122.4119.9718.8019.4817.3013.36
Inventories491473486516526415325
Sundry debtors830751705865750555489
Cash & bank balances8.817.569.438.9622.339.787.64
Loans & advances13810712110295.2076.7977.77
Total current assets1,4681,3381,3211,4921,3931,057899
Total current liabilities603508508546538396421
Net working capital864831813946856661479
Total assets2,1311,9891,8491,8051,5981,2931,075
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash4.586.747.5021.618.816.774.64
Net cash from operating activities25424535913370.41155251
Net cash from investing activities(173)(165)(224)(164)(150)(71.78)(33.21)
Net cash from financing activities(77.44)(82.12)(136)16.5492.03(81.13)(215)
Net change in cash2.69(2.17)(0.76)(14.11)12.802.042.13
Closing cash8.817.569.438.9622.339.787.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+7.5%-5.6%-6.9%+9.1%+15.5%+19.3%-
EBITDA growth+7.4%-9.5%+3.7%-7.0%-24.0%+64.7%-
PBT growth-0.4%-10.1%+5.1%-17.0%-26.8%+99.2%+41.4%
Net income growth+15.9%-2.0%+3.2%-18.9%-26.8%+103.0%-
Revenue CAGR (3Y)-1.9%-1.4%+5.5%+14.6%+16.8%+20.1%+14.8%
EBITDA CAGR (3Y)+0.3%-4.4%-9.8%+5.2%+16.4%+29.4%+11.7%
Profitability & leverage
Net income margin+7.6%+7.0%+6.8%+6.1%+8.2%+13.0%+7.8%
Return on capital employed+12.0%+13.1%+15.0%+15.4%+20.3%+33.4%+20.7%
Return on net worth+13.4%+12.7%+13.9%+14.9%+21.0%+35.8%+23.7%
Debt / equity0.410.440.470.520.460.470.75
Long-term debt / equity0.190.210.190.160.150.220.33
Interest cover14.8316.6514.0714.338.466.7717.26
Efficiency & per share
Fixed asset turnover1.571.661.952.292.192.021.80
Inventory turnover5.324.985.055.215.295.826.31
Debtors turnover3.253.283.223.363.814.133.81
EPS (₹)21.3618.4218.6517.9622.1430.0960.69
Dividend per share (₹)2.001.001.001.001.002.502.00
Book value per share (₹)169.70149.99139.40128.77111.9298.01280.04
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue706627632529579521623515
Revenue growth (YoY)+22.0%+20.4%+1.4%+2.8%+6.6%+5.7%--
Other income2.650.200.831.220.150.391.7111.37
Total expenses609538552486504457534454
EBITDA97.6089.8179.2842.3175.1963.9588.6560.25
EBITDA margin+13.8%+14.3%+12.6%+8.0%+13.0%+12.3%+14.2%+11.7%
Depreciation15.7115.2114.9514.8713.5512.2712.2112.02
Interest7.816.956.596.956.016.827.487.57
Profit before tax76.7367.8558.5721.7155.7845.2570.6752.03
Tax19.0517.0013.61(12.13)14.00(3.39)9.1913.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,2602,1742,2672,4982,2511,9151,635
Revenue growth+4.0%-4.1%-9.3%+11.0%+17.6%+17.1%-
Other income2.5913.574.182.234.779.699.44
Total expenses1,9981,9081,9982,2121,9301,5141,387
Employee cost85.0373.8870.2064.3057.1755.6052.65
EBITDA262265269286321401248
EBITDA margin+11.6%+12.2%+11.9%+11.5%+14.3%+21.0%+15.2%
Depreciation55.6447.7947.6747.2947.3947.6046.67
Interest28.1432.2033.2136.1823.0525.7135.74
Profit before tax181199192205256338175
Tax12.0841.4450.6052.0060.5080.0039.30
Net profit169157142153195258129
Net profit margin+7.5%+7.2%+6.3%+6.1%+8.7%+13.5%+7.9%
EPS (₹)18.5417.2415.4316.5021.0627.6558.23
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital91.2791.2791.9492.6092.6093.2023.30
Reserves & surplus1,3141,1601,0831,022880766598
Shareholders' funds (net worth)1,4051,2511,1751,114972860622
Secured loans350409366436449220250
Unsecured loans70.8310610999.2470.25116128
Total debt421516475535519336378
Total liabilities1,8291,7711,6531,6531,5091,2251,034
Assets
Gross block1,6241,3601,2771,1421,1121,049991
Net block971761722634649631612
Capital work in progress10627322216159.6215.9510.96
Investments72.3042.4029.9728.6228.0324.3220.38
Inventories405407442478488390307
Sundry debtors732702644802712504464
Cash & bank balances4.704.573.822.682.213.813.85
Loans & advances70.3067.0291.4867.4570.8861.9649.77
Total current assets1,2131,1811,1811,3501,273960825
Total current liabilities474429449474456337359
Net working capital739752732875818623467
Total assets1,8291,7711,6531,6531,5091,2251,034
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.282.721.521.492.842.983.94
Net cash from operating activities25422033716239.90154196
Net cash from investing activities(128)(135)(187)(131)(125)(69.03)(29.35)
Net cash from financing activities(126)(84.60)(149)(30.54)84.11(85.28)(168)
Net change in cash0.290.561.200.03(1.35)(0.13)(0.96)
Closing cash4.704.573.822.682.213.813.85
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+4.0%-4.1%-9.3%+11.0%+17.6%+17.1%-
EBITDA growth-1.0%-1.5%-5.9%-10.9%-20.0%+61.9%-
PBT growth-8.8%+3.3%-6.0%-19.8%-24.3%+93.0%+37.1%
Net income growth+7.6%+10.9%-7.2%-21.6%-24.3%+99.2%-
Revenue CAGR (3Y)-3.3%-1.2%+5.8%+15.2%+15.7%+18.9%+14.5%
EBITDA CAGR (3Y)-2.8%-6.2%-12.5%+4.9%+16.6%+29.4%+11.5%
Profitability & leverage
Net income margin+7.5%+7.2%+6.3%+6.1%+8.7%+13.5%+8.3%
Return on capital employed+11.6%+13.5%+13.7%+15.2%+20.4%+32.2%+20.6%
Return on net worth+12.7%+13.0%+12.4%+14.7%+21.3%+34.8%+23.8%
Debt / equity0.350.410.440.510.470.480.74
Long-term debt / equity0.160.200.180.140.150.220.33
Interest cover13.6014.8114.9915.158.427.2717.76
Efficiency & per share
Fixed asset turnover1.521.651.872.222.081.881.71
Inventory turnover5.565.124.935.175.125.496.11
Debtors turnover3.153.233.143.303.703.963.63
EPS (₹)18.5417.2415.4316.5021.0627.6558.23
Dividend per share (₹)2.001.001.001.001.002.502.00
Book value per share (₹)153.92137.10127.83120.34104.9992.23266.86

To see the full year-wise statements and ratios of Aarti Drugs Limited, buy the company report.

Board of directors of Aarti Drugs Limited

Aarti Drugs has 12 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Prakash Moreshwar Patil
Also directs: Aarti Life Science LLP
Managing Director05 Jan 198541 Years 10 MonthsCurrent
Narendra Jagannath Salvi
Also directs: Aarti Pharmalabs Limited, Aarti Pharmachem Limited
Director25 Aug 20206 Years 2 MonthsCurrent
Ankit Vikram Paleja
Also directs: Capacit'e Infraprojects Limited
Director13 Oct 20215 Years 0 MonthsCurrent
Neha Rajen Gada
Also directs: Pinnacle Life Science Private Limited, Infineon Capital Advisors LLP, Sejal Glass Limited and 5 more
Director09 May 20224 Years 5 MonthsCurrent
Harit Pragji Shah
Also directs: Harshit Ventures Limited Liability Partnership, Aarti Life Science LLP, Aarti Speciality Chemicals Limited and 5 more
Whole-Time Director15 Sep 199531 Years 1 MonthsCurrent
Harshit Manilal Savla
Also directs: Harshit Ventures Limited Liability Partnership, Aarti Life Science LLP, Aarti Speciality Chemicals Limited and 5 more
Managing Director02 Jan 198739 Years 10 MonthsCurrent
Showing 6 of 12 current directors. View all directors

Peer comparison

Aarti Drugs Limited is compared with the 7 companies closest to it by revenue in the Chemicals industry (API Manufacturers, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Covalent Laboratories Private Limited₹2,693.24 Cr (FY 2025)-8.0%Hyderabad, Telangana, India
Aarti Drugs Limitedthis company₹2,565.31 Cr (FY 2026)₹194.91 Cr7.6%7.5%1,007Thane, Maharashtra, India
Honour Lab Limited₹2,482.63 Cr (FY 2025)4.0%Hyderabad, Telangana, India
Tagros Chemicals India Private Limited₹2,458.65 Cr (FY 2025)32.0%Chennai, Tamil Nadu, India
Alivus Life Sciences Limited₹2,421.45 Cr (FY 2025)5.0%Solapur, Maharashtra, India
Centrient Pharmaceuticals India Private Limited₹2,240.1 Cr (FY 2025)8.0%Toansa, Punjab, India
Performance Chemiserve Limited₹2,185.27 Cr (FY 2025)73.0%Pune, Maharashtra, India
Unichem Laboratories Limited₹2,146.29 Cr (FY 2025)18.0%Mumbai, Maharashtra, India

To see the full peer comparison of Aarti Drugs Limited, buy the company report.

Auditor

Aarti Drugs Limited is audited by Gokhale & Sathe for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Gokhale & SatheFY 2024103264W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 54.40%, foreign institutional investors hold 1.50%, domestic institutional investors hold 10.30% and retail and other public shareholders hold 33.80%.

Promoters: 54.40%DII (Domestic Institutional): 10.30%FII (Foreign Institutional): 1.50%Retail & Others: 33.80%
Sep 2026
QUARTER
54.40% Promoters
10.30% DII (Domestic Institutional)
1.50% FII (Foreign Institutional)
33.80% Retail & Others
Promoter holding - history
Now 54.40% · Sep 2026High 55.00% · Mar 2026Low 54.40% · Sep 2026
53%53.8%54.5%55.3%56%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 54.70%Mar 2026: 55.00%Jun 2026: 55.00%Sep 2026: 54.40%55.00%54.40%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters54.40%55.00%55.00%54.70%
Public45.60%45.00%45.00%45.30%

Charges & borrowings

Open charges
₹1,570 Cr
Satisfied charges
₹1,214.54 Cr
Breakdown by lending institutions
Axis Bank Limited₹1,570.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
26 Mar 201110277975Axis Bank Limited₹1,570 CrOpen
25 Jan 2024100855330Others₹300 CrSatisfied
20 Sep 2018100209298Others₹64 CrSatisfied
24 Jun 2016100036504Others₹69 CrSatisfied
21 Dec 201510608449The Shamrao Vithal Co Operative Bank Limited₹25 CrSatisfied

To see the full charge records of Aarti Drugs Limited, buy the company report.

Total charge records: 58 View all charges

Deals & funding

Aarti Drugs Limited has 45 deals on record (41 market trades, 4 buybacks); the latest was in May 2025.

Total deals
45
Market trades
41
Buybacks
4

Deals on record (5 of 45)

WhenDealAmountParties
May 2025Market trade₹31.64 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Oct 2023Market trade₹26.63 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Jul 2023Market trade₹58.63 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Jul 2023Market trade₹99.42 CrBuyer: Graviton Research Capital LLP , NK Securities Research Private Limited , Qe Securities
Seller: Graviton Research Capital LLP , NK Securities Research Private Limited , Qe Securities
Mar 2023Market trade₹28.6 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP

To see the full deal history of Aarti Drugs Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Aarti Drugs Limited was last rated by Icra on 20 Jan 2022.

Rating agencyRated onRating
Icra20 Jan 2022

To see the full credit ratings and regulatory alerts of Aarti Drugs Limited, buy the company report.

MSME payment delays

Aarti Drugs Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 80 overdue payments to 20 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 20)

SupplierAmount dueDue sinceReported on
Vinipul Inorganics Private Limited
Qualitech Industrial Producers
an individual supplier
Heetu Chemicals and Alkalies Limited
Chem Mart

To see the full MSME payment records of Aarti Drugs Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Aarti Drugs has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

2
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Aarti Speciality ChemicalsU24230MH2019PLC333306
Pinnacle Life Science PrivatU24232HP2003PTC030912

To see the full group structure of Aarti Drugs Limited, buy the company report.

Employees & EPFO

Aarti Drugs Limited has a workforce of 1,007 employees on its EPFO records as of Feb 04, 2025, across 2 active EPFO establishments.

Employee count
1,007
Active EPFO establishments
2
Employee growth
4.46%

GST

Aarti Drugs has 5 GST registrations: 4 active and 1 cancelled or inactive.

Total GSTINs
5
Active
4
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AAACA4410D1ZEMaharashtraActive01 Jul 2017
27AAACA4410D2ZDMaharashtraActive04 Aug 2018
24AAACA4410D1ZKGujaratActive01 Jul 2017
24AAACA4410D2ZJGujaratActive29 Aug 2024

To see the full GST registrations and return filing status of Aarti Drugs Limited, buy the company report.

Recent activity

Aarti Drugs Limited has 45 board changes on record since 1984: 29 appointments and 16 cessations. The latest: Krishnacharya Govindacharya Akamanchi ceased to be Director on 01 Apr 2024.

Filing
Aarti Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai Ii.
AGM
Aarti Drugs Limited last Annual general meeting of members was held on 24 Sep 2025 as per latest MCA records.
Charges
A charge registered on 25 Jan 2024 via Charge ID 100855330 with Others was fully satisfied on 20 Jun 2024.
Charges
A charge with Axis Bank Limited of Rs. 1,570.00 Cr registered on 26 Mar 2011 with Charge ID 10277975 was modified on 11 Jun 2024.
Ceased
Krishnacharya Govindacharya Akamanchi ceased to be Director.
Ceased
Navin Chapshi Shah ceased to be Director.
Ceased
Priti Paras Savla ceased to be Director.
Appointed
Ajit Eledath Venugopalan was appointed as Director.
Appointed
Hasmukh Bhavanji Dedhia was appointed as Director.
Appointed
Sandeep Madhusudan Joshi was appointed as Director.
Charges
A charge with Others of Rs. 300.00 Cr registered on 25 Jan 2024 with Charge ID 100855330 was modified on 26 Mar 2024.
Charges
A charge with Others amounted to Rs. 300.00 Cr with Charge ID 100855330 was registered on 25 Jan 2024.

175 earlier events are in the company report.

News

Aarti Drugs: Lowers FY27 Volume Growth Expectation To 5-10% From 15% As Customers Cut Back On Purchases And Avoid Stockpiling Due To Rising API Prices.
04 Nov 2026 · Exchange Update
AARTIDRUGS: Q2 REVENUE 7.06B RUPEES VS 5.8B (YOY)
03 Nov 2026 · Exchange Update
AARTIDRUGS: Q2 SL NET PROFIT 577M RUPEES VS 420M (YOY)
03 Nov 2026 · Exchange Update
AARTIDRUGS: Q2 EBITDA 976M RUPEES VS 752M (YOY); Q2 EBITDA MARGIN 13.82% VS 13% (YOY)
03 Nov 2026 · Exchange Update

Frequently asked questions

Aarti Drugs is an active public limited company based in Thane, Maharashtra, India. The company works in specialty chemicals, within the chemicals and materials industry. It was incorporated on 28 September 1984 (42+ years old) and is registered under CIN L37060MH1984PLC055433. Listed on BSE: 524348 and NSE: AARTIDRUGS.

Aarti Drugs reported revenue of ₹2,565.31 Cr for FY 2025-26 (up 7.5% YoY) based on consolidated financials.

Aarti Drugs has 12 current directors:

The latest financial statements of Aarti Drugs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 24 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Aarti Drugs is 27AAACA4410D1ZE, registered in Maharashtra. The company has 5 GST registrations in all, of which 4 are active and 1 is cancelled or inactive. Other active GSTINs include 27AAACA4410D2ZD (Maharashtra), 24AAACA4410D1ZK (Gujarat), 24AAACA4410D2ZJ (Gujarat).

The CIN (Corporate Identification Number) of Aarti Drugs is L37060MH1984PLC055433. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Aarti Drugs is a listed company as per MCA records. Its shares are listed on both BSE (code: 524348) and NSE (symbol: AARTIDRUGS).

Aarti Drugs has 133 court cases on record: 84 filed by the company and 49 filed against it. 35 are pending. Most are in the district courts.

Aarti Drugs was incorporated on 28 September 1984, making it 42+ years old. It is registered with the Registrar of Companies, Mumbai.

Aarti Drugs has 45 deals on record (41 market trades, 4 buybacks); the latest was in May 2025.

The peers of Aarti Drugs by revenue are Covalent Laboratories Private Limited, Honour Lab Limited, Tagros Chemicals India Private Limited, Alivus Life Sciences Limited, Centrient Pharmaceuticals India Private Limited and 2 more, all in the Chemicals industry (API Manufacturers, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Krishnacharya Govindacharya Akamanchi ceased to be Director on 01 Apr 2024. Navin Chapshi Shah ceased to be Director on 01 Apr 2024. Priti Paras Savla ceased to be Director on 01 Apr 2024. Aarti Drugs has 45 board changes on record in total.